- The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
Haematologica (2017-09-02)
Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Luis A Corchete, Irena Misiewicz-Krzeminska, Montserrat Martín-Sánchez, Ana-Alicia López-Iglesias, Esperanza Macarena Algarín, Pedro Mogollón, Andrea Díaz-Tejedor, Teresa Paíno, Brian Tunquist, María-Victoria Mateos, Norma C Gutiérrez, Elena Díaz-Rodriguez, Mercedes Garayoa, Enrique M Ocio
PMID28860344
摘要
Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma patients. The aim of the work herein was to investigate the activity of filanesib in combination with pomalidomide plus dexamethasone backbone, and the mechanisms underlying the potential synergistic effect. The ability of filanesib to enhance the activity of pomalidomide plus dexamethasone was studied in several
材料